InTrack Investment Management Inc Sells 912 Shares of Stryker Co. (NYSE:SYK)

InTrack Investment Management Inc lessened its holdings in shares of Stryker Co. (NYSE:SYK - Free Report) by 23.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,023 shares of the medical technology company's stock after selling 912 shares during the quarter. InTrack Investment Management Inc's holdings in Stryker were worth $1,125,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of SYK. Vanguard Group Inc. increased its holdings in shares of Stryker by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 32,698,828 shares of the medical technology company's stock valued at $11,773,213,000 after purchasing an additional 252,188 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Stryker by 0.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 11,109,722 shares of the medical technology company's stock valued at $4,000,056,000 after acquiring an additional 54,693 shares during the period. FMR LLC lifted its position in Stryker by 10.0% during the fourth quarter. FMR LLC now owns 8,034,844 shares of the medical technology company's stock worth $2,892,946,000 after acquiring an additional 727,850 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Stryker by 2.4% during the fourth quarter. Geode Capital Management LLC now owns 7,073,562 shares of the medical technology company's stock worth $2,539,033,000 after acquiring an additional 168,436 shares during the period. Finally, Norges Bank acquired a new position in shares of Stryker in the fourth quarter valued at approximately $1,710,744,000. Institutional investors and hedge funds own 77.09% of the company's stock.

Stryker Trading Down 0.2%

SYK traded down $0.65 during trading on Thursday, reaching $380.43. 877,833 shares of the company's stock were exchanged, compared to its average volume of 1,330,802. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. Stryker Co. has a one year low of $314.93 and a one year high of $406.19. The firm has a fifty day moving average price of $371.93 and a two-hundred day moving average price of $375.92. The stock has a market capitalization of $145.21 billion, a PE ratio of 49.02, a price-to-earnings-growth ratio of 2.93 and a beta of 0.91.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, topping analysts' consensus estimates of $2.73 by $0.11. Stryker had a net margin of 13.25% and a return on equity of 23.58%. The company had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.68 billion. During the same quarter in the previous year, the business earned $2.50 earnings per share. Stryker's revenue was up 11.9% compared to the same quarter last year. As a group, equities research analysts forecast that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be given a $0.84 dividend. The ex-dividend date is Monday, June 30th. This represents a $3.36 annualized dividend and a yield of 0.88%. Stryker's payout ratio is 45.41%.

Insider Buying and Selling

In other news, Director Ronda E. Stryker sold 200,000 shares of the company's stock in a transaction on Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total value of $75,392,000.00. Following the transaction, the director now owns 3,417,326 shares of the company's stock, valued at approximately $1,288,195,208.96. This represents a 5.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 5.90% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Truist Financial lifted their price target on Stryker from $390.00 to $400.00 and gave the stock a "hold" rating in a report on Monday, May 5th. Citigroup reissued a "buy" rating and set a $455.00 target price (up previously from $443.00) on shares of Stryker in a report on Thursday, May 22nd. JMP Securities restated a "market perform" rating on shares of Stryker in a research note on Monday, May 5th. Needham & Company LLC reissued a "buy" rating and issued a $442.00 price objective on shares of Stryker in a report on Friday, March 21st. Finally, Wall Street Zen lowered shares of Stryker from a "buy" rating to a "hold" rating in a research report on Friday, June 6th. Five investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $427.30.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.